Portal de Periódicos da CAPES

A person‐centred approach to enhance the long‐term health and wellbeing of people living with HIV in Europe

2023; International AIDS Society; Volume: 26; Issue: S1 Linguagem: Inglês

10.1002/jia2.26117

1758-2652

Jeffrey V. Lazarus, Mario Cascio, Jane Anderson, Sini Pasanen, Richard Harding,

Pneumocystis jirovecii pneumonia detection and treatment

Person-centred care is a critical attribute of high-quality healthcare, promoting quality of life, improving an individual's interaction with the health system and valuing people's social networks [1]. Lifesaving antiretroviral therapy is now increasingly widely available around the world, although not all countries have reached their coverage targets related to prevention, diagnosis and linkage to care. As a consequence of the enormous progress made, most people living with HIV are able to grow older rather than dying prematurely [2]. Therefore, it is essential that health systems respond to the changing needs of an ageing population living with HIV, who have comparatively higher multimorbidity (both physical and mental) and experience persistent stigma [3, 4]. To achieve this, person-centred care services for people living with HIV must focus on long-term wellbeing by monitoring and managing multimorbidity, health-related quality of life (HRQoL), stigma and discrimination [5]. In line with WHO's global strategy on HIV for 2022–2030 [2] and UNAIDS' targets set in 2021 [6], a people-centred approach is essential to allow for this transformation of health systems. Health services must offer an integrated response to the evolving health needs and choices of people living with HIV—and this is still not the case in most settings, including high-income countries in Europe [7]. The crisis with health systems during 2020 and the worsening of health outcomes during the COVID-19 pandemic [8] demonstrated the importance of coordination among European countries to protect population health across national borders, especially among the most vulnerable. Against the backdrop of the pandemic, in 2020, the European Union put forward a proposal for a European Health Union [9]. Ambitious policy opportunities were identified, from a proposal for a European Health Data Space, to reinforcing the European Centre for Disease Prevention and Control mandate and pushing forward the European Care Strategy [10]. Person-centricity is at the corej of these health system initiatives, paving the way for personalized healthcare delivery. These initiatives are of particular relevance for people living with HIV and their healthcare services given their multidimensional health and social care needs. A people-centred health system is organized around what is important to people living with HIV, their needs and choices, rather than focusing on individual diseases [5, 11]; it "consciously adopts the perspectives of individuals, families and communities (…), sees them as participants and beneficiaries of trusted health systems that respond (…) in humane and holistic ways" and "acknowledges the experiences and perspectives of health-care providers that may enable or prevent the delivery of [these health services]" [12]. In the context of HIV, people living with HIV must be empowered and supported to make decisions about the degree of self-management that they are capable of and willing to assume in line with their age, gender, socio-economic status and support network. A key objective of a people-centred approach is to ensure that the views, needs and wellbeing of people living with HIV are represented in policy initiatives by prioritizing the enhancement of their long-term health, HRQoL and overall wellbeing, from diagnosis until the end of life [5]. With this goal in mind, in 2021 and 2022, over 60 multidisciplinary HIV organizations and experts from the HIV Outcomes initiative co-developed a set of 27 policy asks and recommendations for European health systems and authorities [13]. Qualitative input was collected with a representation of people living with HIV, clinicians, academics, public health professionals, policymakers and industry representatives. Expert interviews were conducted via a questionnaire and at seven workshops. Entitled "Enhancing long-term health and well-being among people living with HIV," the policy asks were grouped into four areas where policy action is most urgent to improve wellbeing: (1) comorbidity prevention, treatment and management-including mental health; (2) ageing with HIV; (3) patient-reported outcomes measures and national monitoring of HRQoL; and (4) combatting stigma and discrimination. For each area, specific, implementable and translatable recommendations were made for HIV clinics/care providers, national and regional authorities and European Union health policymakers. Priority recommendations are highlighted in Table 1 [13]. Although focusing on monitoring HRQoL may be challenging for countries or health systems with fewer resources available, people living with HIV experience a greater overall burden of multimorbidity in comparison with the general population and reduced HRQoL across all domains. Therefore, actions that can benefit both individual wellbeing and health system costs need to be adopted. This should be in tandem with efforts to increase the numbers of people diagnosed, linked to care and virally suppressed [14]. A particular focus should be placed on reaching people who are diagnosed late as they are at high risk of clinical progression and poor outcomes. Currently, 53% of people newly diagnosed with HIV in the WHO European region are diagnosed late, of whom 51% are aged >50 [15]. We encourage the adoption of these measures by all European Union member states by the end of 2023. The aforementioned policy recommendations are tailored to tackle the shortcomings in healthcare settings for people living with HIV in Europe. Different priority areas of action also may be considered for other regions of the world. JVL reports grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics to his institution, speaker fees from Intercept, Janssen, Novo Nordisk and ViiV and consulting fess from Novavax, outside of the submitted work. JA reports consultancy and speaker fees from Gilead Sciences and speaker fees from ViiV Healthcare, outside of the submitted work. MC, SP and RH have no competing interest to declare. JVL conceived of the paper. MC, JA, SP and RH reviewed the first full draft of the article. All authors were involved in subsequent revisions and approved the final version for submission. The authors are members of the HIV Outcomes initiative (https://hivoutcomes.eu/about-us/team-members/). JVL acknowledges support to ISGlobal from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033 and the 'Generalitat de Catalunya' through the CERCA Programme, outside of the submitted work. The Policy Asks were developed in collaboration with European multidisciplinary experts and members of the HIV Outcomes Initiative, including researchers, HIV clinicians, people living with HIV, patient group representatives and industry. Thank you to everyone at HIV Outcomes. HIV Outcomes, a multi-stakeholder European initiative, was created in 2016 to advance the health-related quality of life of people living with HIV—beyond viral suppression. HIV Outcomes members: HIV Outcomes Steering Group Members: Antonella d'Arminio Monforte: University of Milan; AIDS Action Europe: represented by Sini Pasanen; Children's HIV Association (CHIVA): represented by Amanda Ely and Amanda Williams; European AIDS Treatment Group (EATG): represented by Mario Cascio; Jane Anderson: Homerton University Hospital NHS Foundation Trust, London (Steering Group Co-Chair); National AIDS Trust (NAT): represented by Cheryl Gowar; Nikos Dedes: Positive Voice (Greek association for people living with HIV) (Steering Group Co-Chair); Richard Harding: King's College London; Jeffrey Lazarus: Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona (Steering Group Co-Chair); Stéphan Vernhes: AIDES & Coalition PLUS; and Industry represented by: Andrea Zanaglio (Gilead Sciences) and Rhon Reynolds (ViiV Healthcare). HIV Outcomes general members: Adhara Asociación VIH/SIDA (ADHARA): represented by Diego García and Alejandro Bertó Morán; AFEW International: represented by Yulia Komo; Correlation—European Harm Reduction Network [C-EHRN]: represented by Roberto Pérez-Gayo; Dr Casper Rokx: Erasmus MC; Dr Diana Barger: University of Bordeaux; Dr Patrizia Carrieri: French Institute of Health and Medical Research (INSERM); East Europe & Central Asia Union of PLWH (ECUO): represented by Vladimir Zhovtyak; GAMIAN-Europe: represented by Nigel Olisa; Georg Behrens: Hannover Medical School; Grupo de Ativistas em Tratamentos (GAT Portugal): represented by Luis Mendão; Igor Gordon: Eurasian Harm Reduction Association; Maryan Said; National HIV Nurses Association (NHIVNA): represented by Shaun Watson; Prof Alan Winston–Okeefe: Imperial College London; Prof Anna Mia Ekström: Karolinska Instituet; Prof Caroline Sabin: University College London; Prof Giovanni Guaraldi: University of Modena and Reggio Emilia (UNIMORE); Prof Kyriakos Souliotis: University of Peloponnese & Health Policy Institute; Prof Lars E Eriksson: Karolinska Instituet; Sociedad Española Interdisciplinaria del SIDA (SEISIDA): represented by Dr María José Fuster-Ruíz de Apodaca; Supporting Women with HIV Information Network (SWIFT Network): represented by Yvonne Gilleece; SKUK-Magnus: represented by Miran Solinc; and Terrence Higgins Trust (THT): represented by Richard Angell. HIV Outcomes Observer members: European Centre for Disease Prevention and Control (ECDC); Joint United Nations Programme on HIV/AIDS (UNAIDS); European AIDS Clinical Society (EACS); Fast Track Cities Europe; and UNITE Global Parliamentarians Network (UNITE). HIV Outcomes in-country initiatives: HIV Outcomes Germany; HIV Outcomes Italy; HIV Outcomes Spain; HIV Outcomes Romania; and HIV Outcomes UK.